PERSONALISED MEDICINE FOR BETTER HEALTH
About
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to
- Assess disease risk for several immunological disorders.
- Predict the success of a drug for a specific patient.
- Develop dosing recommendations for new immunological drugs.
Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.
Contact
- +1 (855) 753-9474
- info@plexision.com
- 4424 Penn Ave., #202, Pittsburgh, PA 15224 USA
About Us
Plexision develops cellular biomarkers for personalized diagnostics and drug development in infectious diseases, solid organ transplantation, as well as immuno-oncology. These tests are based on patented technology that measures antigen-specific white blood cells.
Testing services for patients, researchers, and drug developers are provided by Plexision’s CLIA-certified, GMP-compliant central laboratory in Pittsburgh, Pennsylvania.
Plexision’s team consists of highly-trained technologists, cytometrists, clinicians, scientists, bioentrepreneurs, and bioinformaticians.
Plexision currently offers a wide array of lab-developed cell-based diagnostic tests for personalized patient care. The patented technology underlying these testing systems has been used to support custom R&D projects in both the industry and academia.
Plexision’s first product, the FDA-approved PleximmuneTM blood test predicts transplant rejection. PlexCOVID-19, the most recent blood test, measures the risk and severity of COVID-19 infection.
Our technology can be adapted to -
- Assess disease risk for several immunological disorders.
- Predict the success of a drug for a specific patient.
- Develop dosing recommendations for new immunological drugs.
Rakesh Sindhi
Rakesh Sindhi, M.D., is a transplant surgeon, Co-founder of Plexision, Chief Scientific Officer and Chief Executive Officer, and a member of Plexision’s Board of Directors. He is also Raizman- Haney Chair, Professor of Surgery, Co-Director of Pediatric Transplant Surgery, and Director of the Center for Computational Immunogenetics and Drug Repurposing at the University of Pittsburgh; where he developed all technology underlying Plexision's products. This technology is exclusively licensed to Plexision by the University. Sindhi has authored over 25 patents/applications and has authored or co-author over 130 peer-reviewed papers. He has received several grants from the National Institute of Health allowing him to study the immunogenetic basis of transplant rejection and the genetic basis of biliary atresia, the leading congenital cause of liver transplantation in children.
Ashok Reddy
Ashok Reddy is the Director of Operations and has been with Plexision since 2008. He has worked for over three decades in senior management positions, specializing in all aspects of operations. This experience includes personnel management, contract and labor negotiations, client relationships, operational analysis, budgeting, process re-engineering, and workflow optimization. In the last two decades, Reddy has also held operational roles in the information technology and healthcare IT space. He previously worked as the Senior Vice-President of Operations at Infinite Computer Solutions for over a decade before co-founding IQGateway, a predictive analytics company, where he served as the Chief Operating Officer. Reddy also serves as a consultant to Infinite Healthcare Solutions, a company focused on helping veterans.
Rakesh Sindhi
Rakesh Sindhi, M.D., is a transplant surgeon, Co-founder of Plexision, Chief Scientific Officer and Chief Executive Officer, and a member of Plexision’s Board of Directors. He is also Raizman- Haney Chair, Professor of Surgery, Co-Director of Pediatric Transplant Surgery, and Director of the Center for Computational Immunogenetics and Drug Repurposing at the University of Pittsburgh; where he developed all technology underlying Plexision's products. This technology is exclusively licensed to Plexision by the University. Sindhi has authored over 25 patents/applications and has authored or co-author over 130 peer-reviewed papers. He has received several grants from the National Institute of Health allowing him to study the immunogenetic basis of transplant rejection and the genetic basis of biliary atresia, the leading congenital cause of liver transplantation in children.
Ashok Reddy
Ashok Reddy is the Director of Operations and has been with Plexision since 2008. He has worked for over three decades in senior management positions, specializing in all aspects of operations. This experience includes personnel management, contract and labor negotiations, client relationships, operational analysis, budgeting, process re-engineering, and workflow optimization. In the last two decades, Reddy has also held operational roles in the information technology and healthcare IT space. He previously worked as the Senior Vice-President of Operations at Infinite Computer Solutions for over a decade before co-founding IQGateway, a predictive analytics company, where he served as the Chief Operating Officer. Reddy also serves as a consultant to Infinite Healthcare Solutions, a company focused on helping veterans.